"Thank you very much for this outstanding piece, Dr. Packer!"
"Your excellent, beautifully written essay conveys your deep sense of compassion and your respect for human dignity and individuality. It is a lovely piece to read."
"Well said Dr. Packer. You get it."
"Thank you, Dr. Packer, for another wonderful article."
And our personal favorite:
"Bravo Doctor! You've opened Pandora's Box and hopefully, it won't be slammed shut in your face."
These are just a few of our readers' enthusiastic comments about Milton Packer's blog posts from 2018. This Thanksgiving week, MedPage gives special thanks to Milton Packer for raising discussion-worthy topics -- always important and sometimes controversial -- to our readers each and every week.
Here are some of our favorites from the year for your enjoyment:
Perverse Incentives: Do You See What I See?
It's Official! Curing Patients Is Bad For Business
Unbelievable! Electrophysiologists Embrace Alternative Facts
New Apple Watch: The Worst Heart Device Ever?
When Did Guidelines Become Holy Writ?
Disclosures
Packer recently consulted for Actavis, Akcea, Amgen, AstraZeneca, Boehringer Ingelheim, Cardiorentis, Daiichi Sankyo, Gilead, Novo Nordisk, Pfizer, Sanofi, Synthetic Biologics, and Takeda. He chairs the EMPEROR Executive Committee for trials of empagliflozin for the treatment of heart failure. He was previously the co-PI of the PARADIGM-HF trial and serves on the Steering Committee of the PARAGON-HF trial, but has no financial relationship with Novartis.